RxDoctor Payments Data

Amanda Williams, MD

Family Medicine · Greensburg, INNPI 1760839351

Payments from drug & device makers

$4,394in general payments, 2019–2025

Across 235 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi US Services Inc.$780
  • Novartis$306
  • Novo Nordisk$271
  • Pfizer$185
  • Johnson & Johnson$123
  • plus $2K from 33 others

What the payments were for

  • Speaking & faculty fees$78018%
  • Food & beverage$3,61482%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,394 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$5,515
Medicare patients
26
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$110,171
MounjaroTirzepatide35$53,806
EliquisApixaban37$41,836
JardianceEmpagliflozin31$38,925
VraylarCariprazine Hcl27$37,579
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$27,463
FarxigaDapagliflozin Propanediol24$27,139
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$19,327
XareltoRivaroxaban15$16,750
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$10,458
Combivent RespimatIpratropium/Albuterol Sulfate18$8,465
Breo ElliptaFluticasone/Vilanterol13$7,689
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$7,046
Spiriva RespimatTiotropium Bromide13$6,745
SymbicortBudesonide/Formoterol Fumarate16$4,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$271$110,171109 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$50$58,72179 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$73$54,13562 claims
Lilly USA, LLCMounjaro$121$53,80635 claims
PfizerEliquis$185$41,83637 claims
AbbVieVraylar$1,177$37,57927 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$87$37,47456 claims
Johnson & JohnsonXarelto$123$16,75015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Greensburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →